This journal activity provides practitioners with the knowledge needed in the management of Hodgkins disease with incomplete response to first line therapy.

This activity is available from September 2, 2026, through 11:59 p.m. Eastern time on September 1, 2028.

This activity includes four challenging cases in lymphoma and myeloma with a panel of expert radiation oncologists, including one in private practice, and a medical oncologist. 1. Urgent need for debulking in extramedullary relapse of multiple myeloma after BCMA-targeted CAR T-cell therapy.

Given the rarity of lymphomas, many clinicians are not using radiation therapy appropriately in the frontline setting.

The field of cancer is a rapidly evolving field with new treatment approaches moving to clinic on a daily basis. Radiation Oncology is no different. It is extremely difficult for a practicing clinician to stay abreast of new developments in cancer care.

This activity reviews the evolution of field design in lymphoma radiation treatments, as well as offer case-based hands-on practice in contouring GTV, CTV and PTV in a variety of types of lymphomas.

Normal tissue dose-volume constraints are commonly used for lymphoma radiation therapy (RT) planning.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This course is designed to provide clinicians in practice and trainees with a comprehensive review and update of the clinical practice parameters across most major sub-disciplines of radiation oncology, including sarcomas, pediatrics and lymphomas, and the role of radiotherapy in the multidiscipl

The field of cancer is a rapidly evolving field with new treatment approaches moving to clinic on a daily basis. Radiation Oncology is no different. It is extremely difficult for a practicing clinician to stay abreast of new developments in cancer care.

Radiotherapy plays an important role as a consolidation treatment after systemic therapy, either to shorten the course of systemic therapy and reduce hematological, cardiac and fertility toxicity or to reduce the risk of relapse e.g., for bulky masses.

Pages

Subscribe to RSS - Hematologic